SCHEDULE 13G/A: Janus Henderson Group Discloses Significant 9.5% Stake in Mirum Pharmaceuticals

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Mirum Pharmaceuticals, Inc. as of December 31, 2024.

Summary

• Janus Henderson Group plc, a Jersey-based parent holding company and investment adviser, has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Mirum Pharmaceuticals, Inc.
• As of December 31, 2024, Janus Henderson Group plc beneficially owns 4,581,642 shares of Mirum Pharmaceuticals, Inc. Common Stock.
• This represents 9.5% of the total class of securities.
• The shares are held with shared voting power and shared dispositive power, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• Indirect subsidiaries, JHIUS, JHIUKL, and JHIAIFML, are identified as registered investment advisers furnishing investment advice to Managed Portfolios.

Sentiment

Score: 6

Explanation: The filing is neutral in tone, as expected for a Schedule 13G. The disclosure of a significant stake by a major investment firm could be seen as a positive signal of confidence in the issuer, hence a slightly positive score.

Positives

• Janus Henderson Group plc's significant stake (9.5%) indicates a notable institutional investment and potential confidence in Mirum Pharmaceuticals, Inc.'s long-term prospects.
• The certification that the investment is for ordinary course of business, not for control, suggests a passive, potentially stable, investment perspective from a major financial institution.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Mirum Pharmaceuticals, Inc.'s future performance or operations, as its primary purpose is to disclose beneficial ownership.

Management Comments

• The filing includes a certification by Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group plc, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Industry Context

This filing reflects a significant institutional investment in Mirum Pharmaceuticals, Inc., a biotechnology company. Such disclosures are common for investment firms managing large portfolios and indicate their positions in publicly traded companies within the pharmaceutical or biotech sector, providing transparency on major shareholder interests.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which is a regulatory requirement for institutional investors acquiring more than 5% of a company's stock.
• The reported 9.5% stake is a substantial position for an institutional investor, comparable to other large asset managers like BlackRock or Vanguard holding significant, passive stakes in companies across various industries.
• No specific comparable companies, projects, or results are mentioned within this filing itself, as it focuses solely on the ownership disclosure of Janus Henderson Group plc in Mirum Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership. A large institutional stake might be viewed positively, signaling confidence in the company's prospects.
• Mirum Pharmaceuticals, Inc.: Awareness of a significant passive investor, potentially influencing trading volume or stability of the stock.

Key Dates

Keywords

Mirum Pharmaceuticals, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Institutional Ownership, SEC Filing, MRUM